Press Releases

Date Title View
Toggle SummaryJuly 31, 2017 GenMark Diagnostics to Attend Canaccord Genuity's 37th Annual Growth Conference
CARLSBAD, Calif. --(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that President and Chief Executive Officer, Hany Massarany , will attend the 2017 Canaccord Genuity Growth Conference in
View HTML
Toggle SummaryJune 29, 2017 GenMark Achieves CE Mark for its ePlex® Blood Culture Identification Gram-Positive and Gram-Negative Panels
CARLSBAD, Calif. --(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has achieved CE Mark under the European In-Vitro Diagnostic Devices Directive (98/79/EC) for its ePlex Blood Culture
View HTML
Toggle SummaryJune 13, 2017 GenMark Diagnostics Prices Upsized Public Offering of Common Stock
CARLSBAD, Calif. --(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced the upsizing and pricing of its previously announced underwritten public offering of 6,382,978 shares of its common stock
View HTML
Toggle SummaryJune 12, 2017 GenMark Diagnostics Commences Public Offering of Common Stock
CARLSBAD, Calif. --(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that it has commenced an underwritten public offering of $65,000,000 of shares of its common stock.
View HTML
Toggle SummaryJune 12, 2017 GenMark Receives FDA 510(k) Market Clearance for Its ePlex® Instrument and Respiratory Pathogen Panel
The True Sample-to-Answer Solution ™ Brings New Capabilities to Multiplex Molecular Diagnostics CARLSBAD, Calif. --(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has received
View HTML
Toggle SummaryMay 31, 2017 GenMark Diagnostics to Present at the 2017 William Blair Growth Stock Conference
CARLSBAD, Calif. --(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 2017 William Blair Growth Stock Conference in Chicago on Tuesday, June 13, 2017 .
View HTML
Toggle SummaryMay 3, 2017 GenMark Diagnostics to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
CARLSBAD, Calif. --(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas, Nevada , on Tuesday, May 16, 2017 .
View HTML
Toggle SummaryMay 2, 2017 GenMark Diagnostics Reports First Quarter 2017 Results
  First Quarter Revenue Increased 13% Versus Prior Year to $12.5 million Over 70 ePlex ® Customer Agreements in Place Totaling More than 100 Analyzers ePlex Blood Culture Identification Fungal Pathogen Panel CE Mark Achieved   CARLSBAD, Calif.
View HTML
Toggle SummaryApril 20, 2017 GenMark Achieves CE Mark for its ePlex® Blood Culture Identification Fungal Pathogen Panel View HTML
Toggle SummaryApril 18, 2017 GenMark Diagnostics Schedules First Quarter 2017 Financial Results Conference Call for May 2, 2017 View HTML